Figures

1.1 Percentage of invasive isolates tested resistant to selected antibiotics for *Escherichia coli* and *Klebsiella pneumoniae* reported from European countries in 2017 *page* 3
1.2 Cross country comparison of patterns of *Escherichia coli* and *Klebsiella pneumoniae* resistant to third-generation cephalosporins 5
2.1 Relative risk of 30-day mortality of patients with resistant infections relative to those with susceptible infections 24
2.2 Cost of hospitalization for patients with *Escherichia coli* antibiotic-resistant infection and underlying drivers 34
2.3 Projected working-age population loss in OECD countries per year relative to 0% resistance, 2020–2050 36
4.1 Relationship between the number of hospital-acquired infections and investments in infection control 75
5.1 Summary of the pathways of transmission of resistant bacteria between animals, humans and the environment 104
5.2 Different routes for exchange of resistant bacteria or genes from animals to humans and vice versa 112
6.1 Number of new classes of antibiotic discovered or patented each decade 126
6.2 The number of antibiotics in clinical development possibly active against WHO PPL pathogens (2017) and the number of alternative therapies to antibiotics in clinical development (2017) 128
6.3 Framework for developing a holistic incentive package for antibiotic development 134
6.4 Continuum of incentivization across the antibiotic value chain 142
8.1 Ways in which vaccines may reduce antimicrobial resistance 183

Published online by Cambridge University Press

9.1 Systems diagram of the challenge of antimicrobial resistance 211
9.2 "A Fair Shot" pictograph by the Médecins sans Frontières Access Campaign 219
9.3 Dutch Minister of Health, Welfare and Sport, Edith Schippers, poses for photo with US Public Interest Research Group at 2016 UN General Assembly 227
9.4 Book on microbes by children for children from ReAct Latin America 231

Published online by Cambridge University Press